Chris Bajaj, DO
Endocrinology, Diabetes & Metabolism · Fort Worth, TXNPI 1164454369
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $288,290 of the $354,312 with a category attached, or 81.4%. 60 manufacturers reported payments, led by Lilly USA, LLC at 41.2% of the total. 2025 is the largest year on record at $140,015, 8.1 times the $17,360 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,411 payments — averaging $251.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$146K
- Insulet Corporation$107K
- Dexcom, Inc.$68K
- Eli Lilly$11K
- Tandem Diabetes Care, Inc.$5K
- Valeritas, Inc.$4K
- plus $13K from 54 others
Across 781 payments — averaging $553.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$331K
- Kowa Research Institute, Inc.$50K
- Takeda Pharmaceuticals U.S.A., Inc.$31K
- Astrazeneca UK Limited$12K
- Shire North American Group Inc$6K
- AstraZeneca$1K
- plus $1K from 1 others
What the payments were for
- Consulting fees$11,6093%
- Speaking & faculty fees$288,29081%
- Travel & lodging$30,5199%
- Food & beverage$23,6277%
- Education$1900%
- Gifts$590%
- Entertainment$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$120,022
- Omnipod$103,227
- DEXCOM G7 GSS (161)$30,744
- DEXCOM G6 TRANSMITTER$20,860
- DEXCOM STELO GLUCOSE BIOSENSOR$9,306
- DEXCOM CGM$8,050
- DEXCOM G6 CGM SYSTEM$6,588
- LYUMJEV$4,188
- V-GO$3,600
- t-slim insulin pump$3,350
- t:slim X2 insulin pump$1,768
- iLet Bionic Pancreas$335
- InPen$157
- AFREZZA$125
How this compares
$354,312 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 139 | $170,568 |
| TrulicityDulaglutide | 88 | $138,828 |
| JardianceEmpagliflozin | 114 | $122,261 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 82 | $102,740 |
| Tresiba Flextouch U-100Insulin Degludec | 88 | $69,861 |
| OzempicSemaglutide | 46 | $51,070 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 43 | $39,020 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $34,886 |
| FarxigaDapagliflozin Propanediol | 24 | $21,719 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $20,315 |
| ProliaDenosumab | 11 | $18,723 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $17,320 |
| Novolog FlexpenInsulin Aspart | 69 | $17,055 |
| HumalogInsulin Lispro | 54 | $14,420 |
| SynthroidLevothyroxine Sodium | 154 | $13,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $145,931 | $325,475298 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $534 | $161,281157 claims |
| Novo NordiskOzempic, Novolog | $1,230 | $64,29779 claims |
| AstraZenecaFarxiga | $1,830 | $21,71924 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $738 | $20,31514 claims |
| AmgenProlia | $900 | $18,72311 claims |
| AbbVieSynthroid | $666 | $13,695154 claims |
| Clarus Therapeutics Inc.Jatenzo | $58 | $8,37911 claims |
| Antares Pharma, Inc.Xyosted | $173 | $7,70712 claims |
| MerckJanumet | $218 | $6,98712 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $129 | $2,183202 claims |
| PfizerLevoxyl | $162 | $78918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Fort Worth
- Anjanette TanFort Worth$259K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.